公开(公告)号：US20240100047A1

公开(公告)日：2024-03-28

申请号：US18389272

申请日：2023-11-14

申请人： University of South Florida

发明人： Subhra Mohapatra ,  Shyam S. Mohapatra ,  Karthick Mayilsamy ,  Eleni Markoutsa ,  Andrew McGill

IPC分类号： A61K31/4985 ,  A61K9/127 ,  A61K9/51 ,  A61K31/155 ,  A61P31/14

CPC分类号： A61K31/4985 ,  A61K9/127 ,  A61K9/5123 ,  A61K31/155 ,  A61P31/14

摘要： A nanosystem and methods of treating, including prophylactically, coronavirus infections, such as those caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), by administering such nanosystem to a patient is presented. The nanosystem may be comprised of a single or a combination of therapeutic agents, optionally encapsulated in a nanoparticle having a targeting moiety directed to the particular coronavirus. For CoV-2 infections, at least one therapeutic agent, such as the dual DPP4/ACE2 inhibitor sitagliptin, may optionally be encapsulated within a nanoparticle having a fatty acid such as linoleic acid, as the targeting moiety. Administration can occur intranasally prior to infection for prophylactic treatment or post-infection for treatment of the viral infection.

公开(公告)号：US20220062382A1

公开(公告)日：2022-03-03

申请号：US17523009

申请日：2021-11-10

申请人： University of South Florida

发明人： Subhra Mohapatra ,  Shyam S. Mohapatra ,  Karthick Mayilsamy ,  Eleni Markoutsa

IPC分类号： A61K38/19 ,  A61K47/69 ,  A61K48/00 ,  A61K38/17 ,  A61K35/28 ,  A61K47/59 ,  A61K9/00 ,  A61P25/28

摘要： Compositions and methods for treating traumatic brain injury (TBI) are presented. Novel dendriplexes are formed from poly(amidoamine) (PAMAM) dendrimers complexed with shRNA encoding DNA plasmids encapsulating shRNA encoding chemokine ligand 20 (CCL20) gene, chemokine receptor 6 (CCR6) gene, or a combination thereof. The dendriplexes are dually administered, both intranasally and intravenously, prior to administration of stem cells, such as human mesenchymal stem cells (hMSCs) for the treatment of traumatic brain injury (TBI). Administration of the dendriplexes prior to stem cell administration resulted in a decrease in neurodegeneration, neuroinflammation, microgliosis and astrogliosis. In addition, a synergistic increase in brain derived trophic factor (BDNF) was shown by administration of the combination of dendriplex and stem cell administration.

公开(公告)号：US20240065983A1

公开(公告)日：2024-02-29

申请号：US18384528

申请日：2023-10-27

申请人： University of South Florida

发明人： Subhra Mohapatra ,  Shyam S. Mohapatra ,  Karthick Mayilsamy ,  Eleni Markoutsa ,  Andrew McGill

IPC分类号： A61K9/51 ,  A61K31/4439 ,  A61K31/7105 ,  A61P31/14

CPC分类号： A61K9/5123 ,  A61K31/4439 ,  A61K31/7105 ,  A61P31/14

摘要： A multi-functional broad-spectrum antiviral and anti-inflammatory nanosystem and methods of treating, including prophylactically, coronavirus infections, such as those caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), by administering such nanosystem to a patient is presented. The nanosystem may be comprised of a combination of therapeutic agents directed to the particular coronavirus encapsulated in a nanoparticle that is surface coated with a targeting moiety. For CoV-2 infections, an antiviral such as the PPAR-γ agonist leriglitazone (LG) and an siRNA targeting a conserved sequence of the virus can be encapsulated within a nanoparticle surface coated with a fatty acid such as linoleic acid, as the targeting moiety. Administration can occur intranasally prior to infection for prophylactic treatment or post-infection for treatment of the viral infection.

公开(公告)号：US20210315937A1

公开(公告)日：2021-10-14

申请号：US17224831

申请日：2021-04-07

申请人： University of South Florida

发明人： Subhra Mohapatra ,  Shyam S. Mohapatra ,  Mahasweta Das ,  Andrew McGill ,  Taylor Martinez ,  Karthick Mayilsamy

IPC分类号： A61K35/28 ,  A61K31/4439 ,  A61K9/00

摘要： The present application is related to methods of treating ARDS in a subject in need thereof, by administering (a) pioglitazone, or a pharmaceutically acceptable salt thereof, and (b) mesenchymal stromal cells to the subject. Also disclosed herein are methods of treating one or more symptoms of ARDS in a subject in need thereof.